Commentary: Risk/benefit ratio of androgen deprivation treatment for sex offenders

Research output: Contribution to journalArticle

Abstract

Androgen deprivation treatment (ADT) significantly lowers testosterone. That, in turn, can decrease sexual drive, facilitating better self-control and lower recidivism rates among sexually disordered offenders. Potential side effects can include: decreases in bone density; development of a metabolic syndrome involving weight gain, accompanied by changes in glucose and lipid metabolism; and rarely, depression. In the presence of a proper treatment protocol designed either to prevent or to minimize side effects, particularly the development of osteoporosis, the risks associated with ADT are generally within the same range as those associated with many other commonly prescribed psychotropic interventions.

Original languageEnglish (US)
Pages (from-to)59-62
Number of pages4
JournalJournal of the American Academy of Psychiatry and the Law
Volume37
Issue number1
StatePublished - 2009

Fingerprint

Androgens
Odds Ratio
Clinical Protocols
Lipid Metabolism
Bone Density
Osteoporosis
Weight Gain
Testosterone
Glucose
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pathology and Forensic Medicine

Cite this

@article{1bb6be778b21482eac74300b34a76cd5,
title = "Commentary: Risk/benefit ratio of androgen deprivation treatment for sex offenders",
abstract = "Androgen deprivation treatment (ADT) significantly lowers testosterone. That, in turn, can decrease sexual drive, facilitating better self-control and lower recidivism rates among sexually disordered offenders. Potential side effects can include: decreases in bone density; development of a metabolic syndrome involving weight gain, accompanied by changes in glucose and lipid metabolism; and rarely, depression. In the presence of a proper treatment protocol designed either to prevent or to minimize side effects, particularly the development of osteoporosis, the risks associated with ADT are generally within the same range as those associated with many other commonly prescribed psychotropic interventions.",
author = "Berlin, {Frederick S}",
year = "2009",
language = "English (US)",
volume = "37",
pages = "59--62",
journal = "Journal of the American Academy of Psychiatry and the Law",
issn = "1093-6793",
publisher = "American Academy of Psychiatry and the Law",
number = "1",

}

TY - JOUR

T1 - Commentary

T2 - Risk/benefit ratio of androgen deprivation treatment for sex offenders

AU - Berlin, Frederick S

PY - 2009

Y1 - 2009

N2 - Androgen deprivation treatment (ADT) significantly lowers testosterone. That, in turn, can decrease sexual drive, facilitating better self-control and lower recidivism rates among sexually disordered offenders. Potential side effects can include: decreases in bone density; development of a metabolic syndrome involving weight gain, accompanied by changes in glucose and lipid metabolism; and rarely, depression. In the presence of a proper treatment protocol designed either to prevent or to minimize side effects, particularly the development of osteoporosis, the risks associated with ADT are generally within the same range as those associated with many other commonly prescribed psychotropic interventions.

AB - Androgen deprivation treatment (ADT) significantly lowers testosterone. That, in turn, can decrease sexual drive, facilitating better self-control and lower recidivism rates among sexually disordered offenders. Potential side effects can include: decreases in bone density; development of a metabolic syndrome involving weight gain, accompanied by changes in glucose and lipid metabolism; and rarely, depression. In the presence of a proper treatment protocol designed either to prevent or to minimize side effects, particularly the development of osteoporosis, the risks associated with ADT are generally within the same range as those associated with many other commonly prescribed psychotropic interventions.

UR - http://www.scopus.com/inward/record.url?scp=66149123309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149123309&partnerID=8YFLogxK

M3 - Article

C2 - 19297635

AN - SCOPUS:66149123309

VL - 37

SP - 59

EP - 62

JO - Journal of the American Academy of Psychiatry and the Law

JF - Journal of the American Academy of Psychiatry and the Law

SN - 1093-6793

IS - 1

ER -